Its pipeline products include BEAM-101, BEAM-201, BEAM-301, and BEAM-302, which are used for serious diseases. On March 10, Beam Therapeutics Inc. (NASDAQ:BEAM) was upgraded to Buy from Hold Jones ...

We recently published a list of 10 Best Growth Stocks to Invest in for the Next 10 Years. In this article, we are going to take a look at where Beam Therapeutics Inc. (NASDAQ:BEAM) stands against ...

In this article, we are going to take a look at where Beam Therapeutics Inc. (NASDAQ:BEAM) stands against other best growth stocks to invest in for the next 10 years. On March 8, Ben Snider ...

and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.

Its lead programs include BEAM-101 for sickle cell disease (SCD), BEAM-302 for alpha-1 antitrypsin deficiency (AATD), and BEAM-301 for glycogen storage disease type 1a (GSD1a). Beam’s most advanced ...

这项技术使一类新的基因药物能够靶向基因组中的单个碱基，而不会在DNA中造成双链断裂。该公司的投资组合包括基因校正、基因修饰、基因激活、基因沉默和多重编辑。该公司的管道项目包括BEAM-101、ESCAPE、BEAM-302、BEAM-301和BEAM-201。

A glowing red immersive laser artwork will light up the spectacular architecture of The Capitol Theatre as part of Melbourne arts festival Rising.

and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. Receive News & Ratings for Beam Therapeutics Daily - Enter your email address below to receive a ...

Jones Trading：上调Beam Therapeutics(BEAM.US)评级，由持有调整至买入评级, 目标价34.00美元。 Beam Therapeutics（BEAM.US）公司简介：Beam Therapeutics Inc 是一家从事 ...